ProShare Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-4,482
| Closed | -$263K | – | 2042 |
|
|
2023
Q4 | $263K | Buy |
+4,482
| New | +$263K | ﹤0.01% | 1471 |
|
|
2023
Q1 | – | Sell |
-5,550
| Closed | -$251K | – | 1932 |
|
|
2022
Q4 | $251K | Buy |
5,550
+75
| +1% | +$3.4K | ﹤0.01% | 1339 |
|
|
2022
Q3 | $383K | Buy |
5,475
+331
| +6% | +$23.2K | ﹤0.01% | 1017 |
|
|
2022
Q2 | $345K | Sell |
5,144
-1,733
| -25% | -$116K | ﹤0.01% | 1135 |
|
|
2022
Q1 | $565K | Sell |
6,877
-2,149
| -24% | -$177K | ﹤0.01% | 1205 |
|
|
2021
Q4 | $1.32M | Sell |
9,026
-3,089
| -25% | -$453K | ﹤0.01% | 898 |
|
|
2021
Q3 | $2.14M | Buy |
12,115
+2,872
| +31% | +$508K | 0.01% | 701 |
|
|
2021
Q2 | $1.49M | Sell |
9,243
-9,196
| -50% | -$1.49M | ﹤0.01% | 830 |
|
|
2021
Q1 | $3.16M | Buy |
18,439
+1,204
| +7% | +$206K | 0.01% | 564 |
|
|
2020
Q4 | $3.79M | Buy |
17,235
+5,460
| +46% | +$1.2M | 0.01% | 488 |
|
|
2020
Q3 | $1.96M | Sell |
11,775
-196
| -2% | -$32.5K | 0.01% | 575 |
|
|
2020
Q2 | $1.37M | Buy |
11,971
+4,805
| +67% | +$549K | 0.01% | 630 |
|
|
2020
Q1 | $551K | Sell |
7,166
-5,054
| -41% | -$389K | ﹤0.01% | 715 |
|
|
2019
Q4 | $1.58M | Sell |
12,220
-1,519
| -11% | -$196K | 0.01% | 674 |
|
|
2019
Q3 | $1.07M | Buy |
13,739
+944
| +7% | +$73.5K | 0.01% | 726 |
|
|
2019
Q2 | $1.32M | Sell |
12,795
-1,517
| -11% | -$156K | 0.01% | 679 |
|
|
2019
Q1 | $1.05M | Buy |
14,312
+1,167
| +9% | +$85.5K | 0.01% | 737 |
|
|
2018
Q4 | $558K | Buy |
+13,145
| New | +$558K | ﹤0.01% | 914 |
|